cord blood expanded with um171
Cell therapyexperimental
Clinical trial activity
2 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02668315)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- LymphocytesSupplementation
supplementation - lymphocytes
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cord blood expanded with um171
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03441958 | Phase 1/Phase 2 (Phase 2) | Mar 7, 2018 | Centre de Commercialisation en Immunothérapie du Cancer (C3i), Ciusss de L'Est de l'Île de Montréal, ExcellThera |
| NCT02668315 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2016 | Canadian Cancer Society, Canadian Institutes of Health Research (CIHR), Hopital de l'Enfant-Jesus, University of British Columbia, University of Montreal |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Canadian Cancer Society | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Canadian Institutes of Health Research (CIHR) | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Centre de Commercialisation en Immunothérapie du Cancer (C3i) | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Ciusss de L'Est de l'Île de Montréal | Academic/Hospital | 1 | 1 | 1 | 2018 |
| ExcellThera | For profit | 1 | 0 | 1 | 2018 |
| Hopital de l'Enfant-Jesus | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of British Columbia | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Montreal | Academic/Hospital | 1 | 1 | 1 | 2016 |
8 organizations
Page 1 / 1